Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012 |
Resumo: | ABSTRACT For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control. |
id |
ABNEURO-1_c7e928b8a031e827ccfd3281a5bbe53a |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2021001101012 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapyImmunosuppressive AgentsImmunologic FactorsAdrenal Cortex HormonesMultiple SclerosisAutoimmune DiseasesNeurologyABSTRACT For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.Academia Brasileira de Neurologia - ABNEURO2021-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012Arquivos de Neuro-Psiquiatria v.79 n.11 2021reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x-anp-2020-0593info:eu-repo/semantics/openAccessAbrantes,Fabiano FerreiraMoraes,Marianna Pinheiro Moraes deAlbuquerque Filho,José Marcos Vieira deAlencar,Jéssica Monique DiasLopes,Alexandre BussingerPinto,Wladimir Bocca Vieira de RezendeSouza,Paulo Victor Sgobbi deOliveira,Enedina Maria Lobato deOliveira,Acary de Souza Bulle dePedroso,José LuizBarsottini,Orlando Graziani Povoaseng2021-11-17T00:00:00Zoai:scielo:S0004-282X2021001101012Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2021-11-17T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
title |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
spellingShingle |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy Abrantes,Fabiano Ferreira Immunosuppressive Agents Immunologic Factors Adrenal Cortex Hormones Multiple Sclerosis Autoimmune Diseases Neurology |
title_short |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
title_full |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
title_fullStr |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
title_full_unstemmed |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
title_sort |
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy |
author |
Abrantes,Fabiano Ferreira |
author_facet |
Abrantes,Fabiano Ferreira Moraes,Marianna Pinheiro Moraes de Albuquerque Filho,José Marcos Vieira de Alencar,Jéssica Monique Dias Lopes,Alexandre Bussinger Pinto,Wladimir Bocca Vieira de Rezende Souza,Paulo Victor Sgobbi de Oliveira,Enedina Maria Lobato de Oliveira,Acary de Souza Bulle de Pedroso,José Luiz Barsottini,Orlando Graziani Povoas |
author_role |
author |
author2 |
Moraes,Marianna Pinheiro Moraes de Albuquerque Filho,José Marcos Vieira de Alencar,Jéssica Monique Dias Lopes,Alexandre Bussinger Pinto,Wladimir Bocca Vieira de Rezende Souza,Paulo Victor Sgobbi de Oliveira,Enedina Maria Lobato de Oliveira,Acary de Souza Bulle de Pedroso,José Luiz Barsottini,Orlando Graziani Povoas |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Abrantes,Fabiano Ferreira Moraes,Marianna Pinheiro Moraes de Albuquerque Filho,José Marcos Vieira de Alencar,Jéssica Monique Dias Lopes,Alexandre Bussinger Pinto,Wladimir Bocca Vieira de Rezende Souza,Paulo Victor Sgobbi de Oliveira,Enedina Maria Lobato de Oliveira,Acary de Souza Bulle de Pedroso,José Luiz Barsottini,Orlando Graziani Povoas |
dc.subject.por.fl_str_mv |
Immunosuppressive Agents Immunologic Factors Adrenal Cortex Hormones Multiple Sclerosis Autoimmune Diseases Neurology |
topic |
Immunosuppressive Agents Immunologic Factors Adrenal Cortex Hormones Multiple Sclerosis Autoimmune Diseases Neurology |
description |
ABSTRACT For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2021001101012 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0004-282x-anp-2020-0593 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.79 n.11 2021 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212789656748032 |